Nivolumab + Azacitidine
Phase 1Active 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteosarcoma
Conditions
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
Trial Timeline
Oct 3, 2019 → Apr 1, 2026
NCT ID
NCT03628209About Nivolumab + Azacitidine
Nivolumab + Azacitidine is a phase 1 stage product being developed by Bristol Myers Squibb for Osteosarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT03628209. Target conditions include Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03628209 | Phase 1 | Active |
Competing Products
18 competing products in Osteosarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Azenosertib + Gemcitabine | Zentalis Pharmaceuticals | Phase 1/2 | 33 |
| Lenvatinib + Ifosfamide + Etoposide + Lenvatinib | Eisai | Phase 2 | 52 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| Camrelizumab in Combination With Neoadjuvant Chemotherapy | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Olaparib + Ceralasertib | AstraZeneca | Phase 2 | 52 |
| Saracatinib + Placebo | AstraZeneca | Phase 2 | 52 |
| robatumumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| pazopanib | Novartis | Phase 2 | 52 |
| Avelumab | Pfizer | Phase 2 | 51 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cisplatin liposomal | Insmed | Phase 1/2 | 38 |
| Cabozantinib | Ipsen | Phase 2 | 49 |
| Sm-EDTMP | Jazz Pharmaceuticals | Phase 2 | 49 |
| LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). | Lantheus Holdings | Phase 1/2 | 38 |
| REOLYSIN® | Oncolytics Biotech | Phase 2 | 44 |